Abstract Number: 1864 • 2014 ACR/ARHP Annual Meeting
Granulomatosis with Polyangiitis or Microscopic Polyangiitis: Long-Term Outcomes of the Prospective Wegent Trial Comparing Azathioprine Vs Methotrexate for Remission-Maintenance in 126 Patients
Background/Purpose Results of the previously reported randomized–controlled WEGENT trial demonstrated that, at 28 months, methotrexate (MTX) is as effective as azathioprine (AZA) for maintaining remission…Abstract Number: 1853 • 2014 ACR/ARHP Annual Meeting
Persistence and Predictors of Biologic TNFi Therapy Among Biologic naïve Psoriatic Arthritis Patients in a US Registry
Background/Purpose: Registry data regarding biologic DMARD therapy as a mono or combo (combined with a traditional oral DMARD) in subjects with Psoriatic Arthritis (PsA) are…Abstract Number: 1857 • 2014 ACR/ARHP Annual Meeting
Determinants of Annual Healthcare Utilization and Overall Cost of Care in Individuals with Systemic Lupus Erythematosus in a Large Insurance Claims Database: Glucocorticoid Use
Background/Purpose: Newer therapeutic agents in systemic lupus erythematosus (SLE) may increase cost of care but their effect on limiting the duration and the dosage of…Abstract Number: 1839 • 2014 ACR/ARHP Annual Meeting
Risk of Recurrent Non-Melanoma Skin Cancer with Methotrexate and Anti-TNF Use in Rheumatoid Arthritis
Background/Purpose: Methotrexate (MTX) and anti-TNF drugs have been hypothesized to increase the risk of a first non-melanoma skin cancer (NMSC). Among patients with prior NMSC,…Abstract Number: 1838 • 2014 ACR/ARHP Annual Meeting
No Increased Risk of Developing a First Invasive Melanoma in Rheumatoid Arthritis Patients Treated with Biologics: Results of a Collaborative Project of 11 European Biologics Registers
Background/Purpose: Swedish and Danish national biologics registers (*) have reported a possible increase in melanoma risk with TNF inhibitors. Since melanomas are uncommon, the association…Abstract Number: 1837 • 2014 ACR/ARHP Annual Meeting
First Results of a European Registries Collaborative Project to Compare the Spectrum of Lymphomas Between Different Exposure Groups in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is associated with a 2-3 fold increased risk of both Hodgkin and non-Hodgkin lymphoma (HL; NHL). The risk of lymphoma, in…Abstract Number: 1836 • 2014 ACR/ARHP Annual Meeting
Safety of Zoster Vaccination Administration in Rheumatic Patients on Current Biologic Therapy
Background/Purpose Herpes Zoster (HZ) occurs in 1 in 3 people in the U.S. during their lifetime. The greatest risk factor is age. Immune suppression from…Abstract Number: 1835 • 2014 ACR/ARHP Annual Meeting
Anti-Osteoporosis Medication Use after Hip or Vertebral Fracture
Background/Purpose: Current National Osteoporosis Guidelines recommend treatment with an approved osteoporosis medication after hip and vertebral fracture. Only 20% of patients receive osteoporosis therapy after…Abstract Number: 1834 • 2014 ACR/ARHP Annual Meeting
Uptake of the American College of Rheumatology’s (ACR) Rheumatology Clinical Registry (RCR): Quality Measure Summary Data
Background/Purpose: The RCR is designed to provide ACR members with an infrastructure for quality reporting related to rheumatoid arthritis, gout, osteoarthritis, osteoporosis, and drug safety.…Abstract Number: 1833 • 2014 ACR/ARHP Annual Meeting
Quality of Primary Care Management of Patients with and without Rheumatoid Arthritis (RA)
Background/Purpose: Little is known about the quality of care received by patients with multiple chronic conditions in primary care and whether quality care is different…Abstract Number: 1830 • 2014 ACR/ARHP Annual Meeting
A Novel Population Care Model in Rheumatoid Arthritis – Significant Improvement in Quality and Reduction in Cost of Care
Background/Purpose: Rheumatoid arthritis (RA) is a common chronic disease with significant morbidity, mortality, and cost. To optimize care for RA patients, we developed a novel…Abstract Number: 1831 • 2014 ACR/ARHP Annual Meeting
Monitoring Patients with Rheumatoid Arthritis in Routine Care – Experiences from a Treat-to-Target Strategy Using the Danbio Registry
Background/Purpose: Monitoring patients with rheumatoid arthritis (RA) in clinical practice with regular assessment of disease activity (e.g. DAS28) is recommended as a part of a…Abstract Number: 1832 • 2014 ACR/ARHP Annual Meeting
National Quality Forum Measure Achievement and Costs in Rheumatoid Arthritis Patients in a Large Managed Care Population
Background/Purpose: The American College of Rheumatology and National Quality Forum (NQF) recommend monitoring quality measures among rheumatoid arthritis (RA) patients. Previously we described the proportion…Abstract Number: 1829 • 2014 ACR/ARHP Annual Meeting
Role of Fluorinated Steroids in Preventing the Progression of Anti-SSA/Ro Associated Isolated Congenital Heart Block to Disease Beyond the Conduction System
Background/Purpose: The cardiac manifestations of neonatal lupus (cardiac NL) characteristically present as conduction disease. A major concern is the extension of injury beyond the AV…Abstract Number: 1828 • 2014 ACR/ARHP Annual Meeting
Adverse Pregnancy Outcomes in Adolescents and Young Women with Systemic Lupus Erythematosus: A National Estimate
Background/Purpose: Pregnant women with SLE have increased risk of adverse outcomes including lupus flare, spontaneous abortion, preeclampsia/eclampsia, premature birth and maternal death, but pregnancy outcomes…
ACR Meeting Abstracts